Skip to main content
. 2020 Jul 27;15:21–29. doi: 10.2147/CE.S203634

Table 1.

Comparison of Different CINV Prophylactic Treatments in Randomized Pivotal Studies in Cisplatin-Based Regimes

Study and Study Arms Number of Randomized Patients per Arm Cancer Type Complete Response No Significant Nausea
Poli Bigelli et al Cancer. 200339
APR+OND+DEX
OND+DEX

260
263
Lung 36%; Urogenital 39%; Head and neck 8%; other a% Acute: 82.8% vs 68.4% *
Delayed: 67.7% vs 46.8% *
Overall: 62.7% vs 43.3% *
Acute: not performed
Delayed: 73% vs 65%
Overall: 71% vs 64%
Hesketh et al J Clin Oncol. 200340
APR+OND+DEX
OND+DEX

260
261
Lung 42%; Urogenital 23%; other 35% Acute: 89.2% vs 78.1% *
Delayed: 75.4% vs 55.8% *
Overall: 72.7% vs 52.3% *
Acute: 90.6% vs 86.5%
Delayed: 75.3% vs 68.5%
Overall: 73.2% vs 66.0%
Grunberg et al J Clin Oncol. 201141
FOS+OND+DEX
APR+OND+DEX

1147
1175
Lung 47%; GI 21%; Urogenital 15%; other 17% Acute: 89.0% vs 88.0%
Delayed: 74.3% vs 74.2%
Overall: 71.9% vs 72.3%
Acute: not performed
Delayed: not performed
Overall: 70.1% vs 70.4%
Hesketh et al Ann Oncol. 201433
NEPA+DEX
PAL+DEX

135
136
Urogenital 29%; Lung 28%; Head and neck 21%; GI 12%; other 10% Acute: 98.5% vs 89.7% *
Delayed: 90.4% vs 80.1% *
Overall: 89.6% vs 76.5% *
Acute: 98.5% vs 93.4% *
Delayed: 90.4% vs 80.9% *
Overall: 89.6% vs 79.4% *
Rapoport et al Lancet Oncol. 2015 (HEC-1)15
ROL+GRA+DEX
GRA+DEX

264
262
Lung 38%; Head and neck 21%; Urogenital 9%; other 32% Acute: 84% vs 74% *
Delayed: 73% vs 58% *
Overall: 70% vs 56% *
Acute: 86% vs 79% *
Delayed: 73% vs 65% *
Overall: 72% vs 63% *
Rapoport et al Lancet Oncol. 2015 (HEC-2)15
ROL+GRA+DEX
GRA+DEX

271
273
Lung 49%; Head and neck 16%; GI 9%; other 26% Acute: 83% vs 79%
Delayed: 70% vs 62% *
Overall: 68% vs 60%
Acute: 90% vs 86%
Delayed: 75% vs 69%
Overall: 73% vs 68%

Note: *Results are statistically significant.

Abbreviations: CINV, chemotherapy-induced nausea and vomiting; APR, aprepitant; FOS, fosaprepitant; ROL, rolapitant; OND, ondansetron; GRA, granisetron; PALO, palonosetron; NEPA, netupitant-palonosetron; DEX, dexamethasone; GI, gastrointestinal.